Selection of monoclonal antibody E48 IgG or U36 IgG for adjuvant radioimmunotherapy in head and neck cancer patients

被引:20
作者
deBree, R
Roos, JC
Plaizier, MABD
Quak, JJ
vanKamp, GJ
denHollander, W
Snow, GB
vanDongen, GAMS
机构
[1] FREE UNIV AMSTERDAM HOSP, DEPT OTOLARYNGOL HEAD & NECK SURG, NL-1081 HV AMSTERDAM, NETHERLANDS
[2] FREE UNIV AMSTERDAM HOSP, DEPT NUCL MED, NL-1081 HV AMSTERDAM, NETHERLANDS
[3] FREE UNIV AMSTERDAM HOSP, DEPT CLIN CHEM, NL-1081 HV AMSTERDAM, NETHERLANDS
关键词
monoclonal antibodies; head and neck cancer; squamous cell carcinoma; biodistribution; human anti-mouse antibody response; antibody-dependent cellular cytotoxicity;
D O I
10.1038/bjc.1997.179
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Preliminary data from recent clinical radioimmunoscintigraphy studies indicate that Tc-99m-labelled murine monoclonal antibodies (MAbs) E48 and U36 have a similar ability to target squamous cell carcinoma of the head and neck (HNSCC) selectively. In the present study we describe additional aspects of murine and chimeric MAb (mMAb and cMAb) E48 and U36, which might influence the selection of one MAb for adjuvant radioimmunotherapy. To make direct comparison possible, ten patients received 11.2 +/- 0.3 and 11.1 +/- 0.2 mg (n = 5) or 51.1 +/- 0.1 and 51.0 +/- 0.4 mg (n = 5) of both mE48 IgG and mU36 IgG labelled with (131)l and (125)l simultaneously and underwent surgery 7-8 days after injection. The mean uptake of iodine-labelled mE48 IgG and mU36 was highest in tumour tissue, 8.9 +/- 8.9 and 8.2 +/- 4.4 %ID kg(-1) respectively. Tumour to non-tumour ratios for oral mucosa, skin, muscle, blood and bone marrow aspirate were 2.5, 5.5, 25.2, 4.7 and 4.0 respectively in the case of mE48 IgG and 2.3, 4.1, 21.0, 5.8 and 5.8 respectively in the case of mU36 IgG. The distribution of mMAbs E48 and U36 throughout tumours that had been collected in previous studies was heterogeneous when administered at a dose of 1 or 12 mg, and homogeneous when administered at a dose of 52 mg. Administration of mE48 IgG (1-52 mg) resulted in a human anti-mouse antibody response in 12 out of 28 patients, while for mU36 IgG (1-52 mg), this figure was three out of 18 patients. cMAb E48 was shown to be highly effective in mediating antibody-dependent cellular cytotoxicity in vitro, while cMAb U36 and mMAbs E48 and U36 were not effective at all. Rationales are provided that give priority to the start of adjuvant radioimmunotherapy trials with Re-186-labelled cMAb U36 IgG in head and neck cancer patients who are at high risk for the development of locoregional recurrences and distant metastases.
引用
收藏
页码:1049 / 1060
页数:12
相关论文
共 33 条
  • [1] THE EFFECT OF ANTIBODY PROTEIN DOSE ON THE UNIFORMITY OF TUMOR DISTRIBUTION OF RADIOANTIBODIES - AN AUTORADIOGRAPHIC STUDY
    BLUMENTHAL, RD
    FAND, I
    SHARKEY, RM
    BOERMAN, OC
    KASHI, R
    GOLDENBERG, DM
    [J]. CANCER IMMUNOLOGY IMMUNOTHERAPY, 1991, 33 (06) : 351 - 358
  • [2] BRAKENHOFF RH, 1995, CANCER IMMUNOL IMMUN, V40, P191, DOI 10.1007/s002620050162
  • [3] BREITZ HB, 1992, J NUCL MED, V33, P1099
  • [4] BUIST MR, 1995, CANCER IMMUNOL IMMUN, V40, P24, DOI 10.1007/s002620050140
  • [5] TUMOR UPTAKE OF INTRAVENOUSLY ADMINISTERED RADIOLABELED ANTIBODIES IN OVARIAN-CARCINOMA PATIENTS IN RELATION TO ANTIGEN EXPRESSION AND OTHER TUMOR CHARACTERISTICS
    BUIST, MR
    KENEMANS, P
    MOLTHOFF, CFM
    ROOS, JC
    DENHOLLANDER, W
    BRINKHUIS, M
    BAAK, JPA
    [J]. INTERNATIONAL JOURNAL OF CANCER, 1995, 64 (02) : 92 - 98
  • [6] SINGLE-DOSE INTRAPERITONEAL RADIOIMMUNOTHERAPY WITH THE MURINE MONOCLONAL-ANTIBODY I-131 MOV18 - CLINICAL-RESULTS IN PATIENTS WITH MINIMAL RESIDUAL DISEASE OF OVARIAN-CANCER
    CRIPPA, F
    BOLIS, G
    SEREGNI, E
    GAVONI, N
    SCARFONE, G
    FERRARIS, C
    BURAGGI, GL
    BOMBARDIERI, E
    [J]. EUROPEAN JOURNAL OF CANCER, 1995, 31A (05) : 686 - 690
  • [7] DEBREE R, 1995, CLIN CANCER RES, V1, P277
  • [8] DEBREE R, 1994, J NUCL MED, V35, P775
  • [9] deBree R, 1995, CLIN CANCER RES, V1, P591
  • [10] CLINICAL SCREENING OF MONOCLONAL-ANTIBODIES 323/A3, CSF-25 AND K928 FOR SUITABILITY OF TARGETING TUMORS IN THE UPPER AERODIGESTIVE AND RESPIRATORY-TRACT
    DEBREE, R
    ROOS, JC
    QUAK, JJ
    DENHOLLANDER, W
    SNOW, GB
    VANDONGEN, GAMS
    [J]. NUCLEAR MEDICINE COMMUNICATIONS, 1994, 15 (08) : 613 - 627